SAN DIEGO–(BUSINESS WIRE)–Encodia, a privately held biotech firm growing next-generation options for proteomics analysis, introduced the hiring of Nigel Beard, Ph.D., as Chief Know-how Officer (CTO).
Dr. Beard has an achieved observe document of bringing transformative life sciences merchandise to market. He most lately served as CTO and Senior Vice President (SVP) of Operations at Mission Bio, the place he launched and scaled Tapestri, a platform for multiomic single cell evaluation. Previous to that, he served as Chief Working Officer (COO) and CTO at Feetz, Inc., served as Head of R&D, Human Identification Enterprise at Life Applied sciences, the place he led the mixing of quite a few acquisitions, and as Senior Program Supervisor at Utilized Biosystems. Beard can be a Board Member at Savran Applied sciences, Inc.
As Encodia’s Chief Know-how Officer, Beard will lead a proficient and progressive workforce to develop and scale Encodia’s breakthroughs. The merchandise and strategies developed by this workforce will present unprecedented perception into the proteome, essentially the most dynamic and difficult stage of biology’s central dogma.
“I’m delighted to affix Encodia at a time of speedy business development, particularly in high-throughput platforms and organic huge information units. To speed up our contributions, we’re including robust scientific and technical expertise for product improvement and commercialization,” Beard stated in a press release. “Having devoted my profession to genomics and product improvement, I’m honored to be becoming a member of the co-founder of Illumina and the proficient workforce at Encodia in constructing a rare firm that may allow proteomics to really enter the organic data age. Our platform will propel our understanding of advanced and persistent illnesses, assist reveal elusive cures, and allow higher affected person outcomes.”
Beard succeeds Kevin Gunderson, an organization co-founder who architected and led Encodia’s earliest analysis efforts.
“Kevin is a rare innovator who holds greater than 70 patents and patents pending for innovations in a broad number of scientific disciplines. His presents helped flip ideas into working prototypes that Encodia is now refining and getting ready to deliver to market,” stated Mark Chee Ph.D., Co-founder and President of Encodia. “As our new CTO, Nigel will advance the product in improvement to full commercialization, and we’re thrilled that he’s becoming a member of our workforce at such an thrilling time!”
Encodia is a privately held biotechnology firm bringing the facility of sequencing to proteomics. The corporate’s patented ProteoCode expertise permits extremely scalable protein evaluation by way of an accessible and easy-to-use benchtop instrument. Instruments using Encodia’s ProteoCode expertise will drive new organic understanding with affect in data-driven drug discovery and improvement, new excessive complexity diagnostics, and past. For extra data, please go to www.encodia.com.